Detalhe da pesquisa
1.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
; 124(9): 1581-1591, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723394
2.
Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues.
Cancer Discov
; 14(6): 953-964, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501975
3.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
4.
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Clin Cancer Res
; 28(1): 137-149, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593528
5.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 5258, 2022 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071033
6.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clin Cancer Res
; 26(14): 3720-3731, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220884
7.
In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins.
Biosci Rep
; 37(2)2017 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28396517
8.
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 6928, 2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376284
9.
STUB1 mutations in autosomal recessive ataxias - evidence for mutation-specific clinical heterogeneity.
Orphanet J Rare Dis
; 9: 146, 2014 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25258038